Efficacy and tolerability of 12-weeks treatment with lipanthyl supra or trichol in Indonesian patients with dyslipidemia.

Supari, Siti Fadilah; Raharjo, Sunu Budhi; Liastuti, Lies Dina; Basha, Adnil.
Artículo en Inglés | IMSEAR | ID: sea-149068

Documentos relacionados

  1. Quantitative Investigation of Intestinal Drug Absorption Enhancement by Drug-Rich Nanodroplets Generated via Liquid-Liquid Phase Separation.
  2. The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia.
  3. Insights into Adsorptive Drug Loading on Silica Aerogels from Supercritical CO<sub>2</sub>.
  4. Neonatal administration of fenofibrate had no developmental programming effect on the lipid profile and relative leucocyte telomere lengths of adolescent rats fed a high-fructose diet postnatally.
  5. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
  6. Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?
  7. Visualizing the Journey of Fenofibrate through the Rat Gastrointestinal Tract by Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging.
  8. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
  9. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
  10. Inhibition of tumor migration and invasion by fenofibrate via suppressing epithelial-mesenchymal transition in breast cancers.